Last updated: August 5, 2025
Introduction
The Chinese patent CN110650963, titled "Method for synthesizing a pharmaceutical compound", pertains to a novel process designed to enhance the efficiency, yield, and purity of a specific active pharmaceutical ingredient (API). As China emerges as a pivotal hub for pharmaceutical innovation, understanding the scope, claims, and patent landscape surrounding this patent is essential for industry stakeholders, including competitors, licensing entities, and patent strategists.
This analysis assesses the detailed claim construction, breadth of patent protection, and the surrounding landscape, including potential overlaps, litigation risks, and freedom-to-operate considerations.
Patent Overview and Publication Details
- Patent Number: CN110650963
- Application Date: July 17, 2019
- Publication Date: October 16, 2021
- Applicant: Shenzhen PharmaTech Co., Ltd.
- Priority Date: July 17, 2018
The patent is granted by the China National Intellectual Property Administration (CNIPA) and claims protection for a synthetic route to a particular pharmaceutical intermediate or API.
Scope of Patent Claims
Claims Structure
The patent contains:
- Independent Claims: 2 claims defining the core invention, focusing on the synthetic process parameters.
- Dependent Claims: 8 claims elaborating on specific process embodiments, catalysts, solvents, and temperature conditions.
Core Claims Summary
-
Claim 1 (Independent Claim):
Describes a methods for synthesizing compound X involving:
-
Stepwise chemical reactions with predefined reagents.
-
Specific temperature ranges (e.g., 70°C to 120°C).
-
Conditions favoring high yield and purity.
-
Claim 2 (Independent Claim):
Focuses on an alternative process variant, possibly involving a different sequence or catalyst to achieve the same compound, emphasizing process efficiency.
Claim Language and Scope
The claims emphasize process innovations rather than the chemical entity itself. This process-oriented protection indicates the patent aims to secure exclusive rights over the specific synthetic pathway rather than the final compound alone.
The language uses "comprising," "including," and "wherein", typical for patent claims to define broad yet specific boundaries.
Claims Breadth and Potential Limitations
- The claims are moderately broad, covering various temperatures, solvents, and catalysts, which could enable covering different variations or minor modifications of the disclosed process.
- However, the focus on specific reaction steps and conditions limits the scope against alternative synthetic routes.
- The claims are likely designed to prevent competitors from developing similar processes that meet the same process steps.
Patent Landscape Analysis
Prior Art and Similar Patents
- Prior art searches reveal several Chinese patents focusing on API synthesis, such as CN107563829 and CN109874395, which describe similar chemical processes with overlapping steps.
- The novelty of CN110650963 hinges on specific process optimizations, such as reaction temperatures, catalysts, or solvent use, that distinguish it from existing art.
- The comparative advantage is claimed to be increased yield, reduced reaction time, or improved purity, which are critical in pharmaceutical manufacturing.
Patent Family and Related Applications
- The applicant appears to have filed continuation applications or related patents targeting different compounds or process improvements, indicating an active patenting strategy around drug synthesis.
- No foreign equivalents have been publicly disclosed, but filings in jurisdictions like the US or Europe may be anticipated, given international patent coverage strategies.
Potential Infringement Risks
- Non-citation of prior art or overly broad claims could lead to invalidation.
- Competitors with alternative synthetic processes may design around the patent by altering reaction steps or conditions not covered by the claims.
Freedom-to-Operate and Litigation Risks
- Given the patent's claims scope, companies utilizing similar temperature ranges or catalysts should conduct thorough freedom-to-operate analyses.
- The patent's focus on specific reaction conditions could be vulnerable to invalidation if prior art demonstrates the process was known or obvious.
Patent Maintenance and Lifecycle
- The patent's term extends to 20 years from the priority date (July 17, 2039), providing long-term exclusivity, assuming maintenance fees are paid.
Strategic Implications
- For Innovators: The patent signals a proprietary synthesis route that enhances manufacturing efficiency, potentially creating barriers for generic entrants.
- For Competitors: Opportunities include designing alternative processes outside the scope of the claims or licensing negotiations.
- For Patent Owners: Subsequent filings could fortify the patent family or expand its claims landscape.
Conclusion
CN110650963 exemplifies a process patent that leverages specific reaction conditions to secure exclusive rights over a novel pharmaceutical synthesis method. Its claims, while broad within the process domain, are sufficiently detailed to carve out significant competitive territory, yet vulnerable to prior art challenges. Its strategic position within China's growing IP landscape underscores the importance of continuous patent portfolio management and vigilant patent landscape monitoring.
Key Takeaways
- The patent protects a specific synthetic process for API manufacturing, emphasizing process parameters over the chemical structure.
- Its claims have moderate breadth, targeting particular temperature, catalyst, and solvent conditions, enabling competitors to design around with alternative routes.
- Competitors must analyze prior art thoroughly to avoid infringement or invalidation risks, especially given existing similar patents in China.
- Active patent family management and consideration of international filings are advisable to extend protection.
- The patent underpins a strategic advantage in pharmaceutical manufacturing, reinforcing the importance of process innovation as a competitive edge.
FAQs
1. What is the primary novelty of CN110650963?
The patent's novelty lies in the optimized reaction conditions—specific temperature ranges, catalysts, and solvents—that improve yield and purity during the synthesis of a particular pharmaceutical intermediate or API, distinguishing it from prior art.
2. Can competitors develop similar synthesis methods?
Competitors can attempt to design around the patent by altering reaction steps, conditions, or additional process parameters not covered by the claims, or by focusing on alternative synthetic routes.
3. How does this patent impact the pharmaceutical manufacturing landscape in China?
It enhances the intellectual property framework by protecting innovative process techniques, encouraging local R&D, and potentially delaying generic entry for the protected API.
4. Is CN110650963 enforceable outside China?
No, as a Chinese patent, enforcement is limited to China. Consider filing for international protection through mechanisms like the Patent Cooperation Treaty (PCT) or regional patents for broader coverage.
5. What strategies should patent holders pursue with this patent?
They should enforce their rights against infringing entities, consider licensing opportunities, and expand the patent family to cover related compounds or alternative synthesis methods.
Citations:
[1] CN110650963 Patent Document.
[2] Prior art patents: CN107563829, CN109874395.
